Company intelligence / Profile preview
Panbela Therapeutics
Waconia, Minnesota, United Statespanbela.com ↗
- Ownership
- Public · PBLA
- Employees
- ~8
- Development stage
- Phase 3
01
Overview
Panbela’s lead asset ivospemin (SBP‑101) has shown promising results in clinical studies for metastatic pancreatic ductal adenocarcinoma with a median overall survival of 14.6 months and an objective response rate of 48%, both exceeding typical outcomes for standard-of-care regimens. The ongoing global Phase III ASPIRE trial continues after three positive safety reviews by the DSMB. Flynpovi™ for FAP has completed pivotal trials and additional indications are being explored across their pipeline.
- Therapeutic areas
- GastroenterologyOncologyEndocrinology
- Modalities
- small molecules (notably polyamine analogues and metabolic inhibitors)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Johns Hopkins University School of Medicine research agreement for development of ivospemin/SBP‑101Clinical collaborations with Moffitt Cancer Center on STK11 mutant NSCLC programFunding partnership with Nant Capital LLC ($12 million investment)
04
Financials
- Market cap
- $485
- Total revenue
- $0
- Enterprise value
- $6.3M
Beyond the preview
Go deeper on Panbela Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panbela Therapeutics.